Indeed, Emens et al. found targeting PDL-1 with atezolizumab in combination with trastuzumab emtansine (T-DM1) did not demonstrate a clinically significant PFS in HER2+ advanced BC patients, and that this combo therapy was correlated with detrimental effects. This evidence concerns the gene ERBB2 and breast cancer.